Laurus Labs Q2 Review: Healthy Momentum In CDMO, FDF; Earnings Upcycle Intact - Motilal Oswal Maintains 'Buy'

1 day ago 2

ARTICLE AD BOX

Motilal Oswal maintains 'Buy' on Laurus Labs, sees upto 19% upside potential.

24 Oct 2025, 10:31 AM IST i

24 Oct 2025, 10:31 AM IST

24 Oct 2025, 10:31 AM IST

<div class="paragraphs"><p>Laurus Labs’ Q2 FY26 revenue grew 35.1% YoY to Rs 16.5 billion.</p><p>(Photo source: company website)</p></div>

Laurus Labs’ Q2 FY26 revenue grew 35.1% YoY to Rs 16.5 billion.

(Photo source: company website)

The non-ARV formulation sales have witnessed a healthy scale-up QoQ, fueled by newer introductions and higher off-take of existing products. Laurus Labs has shown encouraging performance in the ARV segment, led by higher volumes of products sold during the quarter.

To continue reading this story

You must be an existing Premium User

Already a Premium User?

Read Entire Article